AKBA Akebia Therapeutics, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AKBA matters now
Akebia Therapeutics, Inc. (AKBA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.40 with -2.10% on the session and $375.6M in market capitalization; recent performance reads 1-month +19.54% and YTD -33.54%.
The latest financial table shown here is Q1 2026, with revenue of $53.5M, net income of $-9.1M, and EPS of $-0.03. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 20.9%.
The latest indexable market news headline is "Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $4.00; recent insider activity includes Vickers Philip J. filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
10.44
P/S
1.24
EV/EBITDA
-23.77
DCF Value
$-4.03
FCF Yield
20.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.9%
Operating Margin
2.3%
Net Margin
-8.8%
ROE
-62.7%
ROA
-5.7%
ROIC
2.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $53.5M | $-9.1M | $-0.03 |
| Q4 2025 | $57.6M | $-12.2M | $-0.05 |
| FY 2025 | $236.2M | $-5.3M | $-0.02 |
| Q3 2025 | $58.8M | $540.0K | $0.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$4.00
Target (Median)
$4.00
Target Range
$4.00 - $4.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.25
Akebia Therapeutics, Inc., established in 2007 and headquartered in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and commercializing therapies for patients suffering from kidney diseases. The firm's leading experimental drug, vadadustat, is an oral treatment currently in Phase III clinical trials. Its purpose is to address anemia resulting from chronic kidney disease (CKD) in adult patients, encompassing both those dependent on dialysis and those who are not. Akebia also markets Auryxia, a ferric citrate product used to manage serum phosphorus levels in adult CKD patients undergoing dialysis, and to treat iron deficiency anemia in adult CKD patients who are not on dialysis. The company has several key collaboration agreements: with Otsuka Pharmaceutical Co. Ltd. for vadadustat's development and commercialization across major regions including the United States, European Union, Russia, China, Australia, Canada, and the Middle East; with Mitsubishi Tanabe Pharma Corporation for vadadustat in Japan and other Asian territories; and a research and licensing deal with Janssen Pharmaceutica NV pertaining to hypoxia-inducible factor prolyl hydroxylase targeted compounds globally.